Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study

by Martínez, E, Arranz, JA, Podzamczer, D, Lonca, M, Sanz, J, Barragán, P, Knobel, H, Ribera, E, Gutierrez, F, Valero, S, Clotet, B, Dalmau, D, Segura, F, Arribas, JR, Barrufet, P, Santos, I, Payeras, A, de Lazzari, E, Pich, J, Gatell, J
Published 2010

Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL

by Casado, JL, Domingo, P, Rubio, R, Antela, A, Lopez-Ruz, MA, Castro, A, Portilla, J, Ribera, E, Podzamczer, D, Oteo, JA, Galindo, J, Otero, S, Lozano, F, Estrada, V, Moltó, J, Moreno, S
Published 2010

Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine

by Ellefsen-Lavoie, K, Rockstroh, J, Pollard, R, Pantaleo, G, Podzamczer, D, Asmuth, D, van Lunzen, J, Arastéh, K, Schürmann, D, Peters, B, Clotet, B, Hardy, D, Lazzarin, A, Gatell, J, Sommerfelt, MA, Baksaas, I, Wendel-Hansen, V, Sørensen, B
Published 2012

CD4 response, lipid changes and liver outcome in 506 patients receiving nevirapine-based regimens for a median of 9 years

by Podzamczer, D, Tiraboschi, JM, Mallolas, J, Cárdenes, MA, Casas, E, Castro, A, Echevarria, S, Leal, M, Bernanldo de Quirós, JC Lopez, Moreno, S, Puig, T, Ribera, E, Villalonga, C, Gomez Sirvent, JL, Garcia Heranejos, JA, Lopez-Aldeguer, J, Barrufet, P, Force, L, Santos, I, Sanz, J
Published 2010